FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2963299327> ?p ?o ?g. }

• W2963299327 endingPage "1198" @default.
• W2963299327 startingPage "1188" @default.
• W2963299327 abstract "Cligosiban is an orally administered, centrally penetrant oxytocin receptor antagonist being developed to treat premature ejaculation (PE).To determine the efficacy of 3 dose levels of cligosiban caplets to prolong intravaginal ejaculation latency time (IELT) and improve patient-reported outcomes in men with lifelong PE.Patients recorded details of at least 4 sexual intercourse events during a 4-week run-in period, after which they underwent baseline assessments. Patients were eligible for the study if their stopwatch-assessed IELT was ≤1 minute in ≥75% of intercourse attempts and if they met other diagnostic criteria for lifelong PE. Eligible patients (target 220 evaluable) were randomized to double-blind cligosiban 400, 800, or 1200 mg or matching placebo caplets (to be taken 1 to 6 hours prior to sexual activity). Assessments were conducted at 2, 4, and 8 weeks.Efficacy measures were comprised of IELT, self-rating of ejaculation control and ejaculation-related distress (recorded in an electronic diary after each intercourse attempt), premature ejaculation profile, Patient's Global Impression of Severity, and the Clinical Global Impression of Change.There were no clinically or statistically significant differences between cligosiban (at any dose level) and placebo for the primary endpoint (change in geometric IELT) or any of the secondary endpoints. Cligosiban was well tolerated with a side-effect profile similar to placebo.This Phase IIb study failed to demonstrate the potential for cligosiban, an oxytocin antagonist, to successfully treat symptoms of severe lifelong PE at doses up to 1200 mg.This was a Phase IIb, randomized, double-blind, placebo-controlled study that was adequately powered but failed to detect a clinically meaningful or statistical difference in change in IELT between cligosiban at 3 dose levels and placebo. This is in contrast to a similarly designed proof-of-concept study where cligosiban was flexibly dosed at doses up to 800 mg and did demonstrate clinically meaningful and statistically significant changes in efficacy parameters. The reasons for this disparity are not known.Cligosiban was well tolerated but failed to demonstrate efficacy for the treatment of men with lifelong PE at doses up to 1200 mg. Althof S, Osterloh IH, Muirhead GJ, et al. The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX). J Sex Med 2019; 16:1188-1198." @default.
• W2963299327 created "2019-07-30" @default.
• W2963299327 creator A5002966804 @default.
• W2963299327 creator A5003867723 @default.
• W2963299327 creator A5004280343 @default.
• W2963299327 creator A5004913350 @default.
• W2963299327 creator A5017687851 @default.
• W2963299327 creator A5020538296 @default.
• W2963299327 creator A5025611081 @default.
• W2963299327 creator A5031148055 @default.
• W2963299327 creator A5031354331 @default.
• W2963299327 creator A5032353869 @default.
• W2963299327 creator A5036302146 @default.
• W2963299327 creator A5036776576 @default.
• W2963299327 creator A5038425772 @default.
• W2963299327 creator A5042306463 @default.
• W2963299327 creator A5048164060 @default.
• W2963299327 creator A5048609607 @default.
• W2963299327 creator A5051113606 @default.
• W2963299327 creator A5054919199 @default.
• W2963299327 creator A5055208378 @default.
• W2963299327 creator A5056338234 @default.
• W2963299327 creator A5056471991 @default.
• W2963299327 creator A5056968649 @default.
• W2963299327 creator A5061029367 @default.
• W2963299327 creator A5061227621 @default.
• W2963299327 creator A5068385161 @default.
• W2963299327 creator A5071885632 @default.
• W2963299327 creator A5073648396 @default.
• W2963299327 creator A5077255430 @default.
• W2963299327 creator A5078191472 @default.
• W2963299327 creator A5079044411 @default.
• W2963299327 creator A5082748705 @default.
• W2963299327 creator A5084392936 @default.
• W2963299327 creator A5084513212 @default.
• W2963299327 creator A5086539322 @default.
• W2963299327 creator A5089437464 @default.
• W2963299327 date "2019-08-01" @default.
• W2963299327 modified "2023-10-04" @default.
• W2963299327 title "The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX)" @default.
• W2963299327 cites W1493050084 @default.
• W2963299327 cites W1934389045 @default.
• W2963299327 cites W1974447401 @default.
• W2963299327 cites W1979070058 @default.
• W2963299327 cites W2058172530 @default.
• W2963299327 cites W2072868968 @default.
• W2963299327 cites W2086240335 @default.
• W2963299327 cites W2091455054 @default.
• W2963299327 cites W2102716890 @default.
• W2963299327 cites W2132322340 @default.
• W2963299327 cites W2140500966 @default.
• W2963299327 cites W2167725431 @default.
• W2963299327 cites W2171499783 @default.
• W2963299327 cites W2896289671 @default.
• W2963299327 cites W2963299327 @default.
• W2963299327 cites W4235219538 @default.
• W2963299327 doi "https://doi.org/10.1016/j.jsxm.2019.05.015" @default.
• W2963299327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31351660" @default.
• W2963299327 hasPublicationYear "2019" @default.
• W2963299327 type Work @default.
• W2963299327 sameAs 2963299327 @default.
• W2963299327 citedByCount "12" @default.
• W2963299327 countsByYear W29632993272019 @default.
• W2963299327 countsByYear W29632993272020 @default.
• W2963299327 countsByYear W29632993272021 @default.
• W2963299327 countsByYear W29632993272022 @default.
• W2963299327 crossrefType "journal-article" @default.
• W2963299327 hasAuthorship W2963299327A5002966804 @default.
• W2963299327 hasAuthorship W2963299327A5003867723 @default.
• W2963299327 hasAuthorship W2963299327A5004280343 @default.
• W2963299327 hasAuthorship W2963299327A5004913350 @default.
• W2963299327 hasAuthorship W2963299327A5017687851 @default.
• W2963299327 hasAuthorship W2963299327A5020538296 @default.
• W2963299327 hasAuthorship W2963299327A5025611081 @default.
• W2963299327 hasAuthorship W2963299327A5031148055 @default.
• W2963299327 hasAuthorship W2963299327A5031354331 @default.
• W2963299327 hasAuthorship W2963299327A5032353869 @default.
• W2963299327 hasAuthorship W2963299327A5036302146 @default.
• W2963299327 hasAuthorship W2963299327A5036776576 @default.
• W2963299327 hasAuthorship W2963299327A5038425772 @default.
• W2963299327 hasAuthorship W2963299327A5042306463 @default.
• W2963299327 hasAuthorship W2963299327A5048164060 @default.
• W2963299327 hasAuthorship W2963299327A5048609607 @default.
• W2963299327 hasAuthorship W2963299327A5051113606 @default.
• W2963299327 hasAuthorship W2963299327A5054919199 @default.
• W2963299327 hasAuthorship W2963299327A5055208378 @default.
• W2963299327 hasAuthorship W2963299327A5056338234 @default.
• W2963299327 hasAuthorship W2963299327A5056471991 @default.
• W2963299327 hasAuthorship W2963299327A5056968649 @default.
• W2963299327 hasAuthorship W2963299327A5061029367 @default.
• W2963299327 hasAuthorship W2963299327A5061227621 @default.
• W2963299327 hasAuthorship W2963299327A5068385161 @default.
• W2963299327 hasAuthorship W2963299327A5071885632 @default.
• W2963299327 hasAuthorship W2963299327A5073648396 @default.
• W2963299327 hasAuthorship W2963299327A5077255430 @default.
• W2963299327 hasAuthorship W2963299327A5078191472 @default.
• W2963299327 hasAuthorship W2963299327A5079044411 @default.
• W2963299327 hasAuthorship W2963299327A5082748705 @default.

• next